U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. News & Events
  3. Congressional Testimony
  4. Stopping the Spread of Monkeypox: Examining the Federal Response - 09/14/2022
  1. Congressional Testimony

Testimony | In Person

Event Title
Stopping the Spread of Monkeypox: Examining the Federal Response
September 14, 2022

Testimony of
Robert M. Califf, M.D., MACC
Commissioner of Food and Drugs - Food and Drug Administration

INTRODUCTION

Chair Murray, Ranking Member Burr, distinguished members of the Committee, thank you for this opportunity to testify before you today to describe the Food and Drug Administration’s (FDA’s or the Agency’s) monkeypox disease response efforts. All of our efforts are in close coordination and collaboration with our partners, both within the Department of Health and Human Services (HHS) and across the federal government, to help ensure the development, authorization, licensure, approval, and availability of critical, safe, and effective medical products to address the monkeypox virus public health emergency.

Click for full version of testimony

Back to Top